Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool October 25, 2006 Brian Lawler	Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool August 1, 2008 Brian Lawler	Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool January 29, 2007 Brian Lawler	ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.
The Motley Fool September 11, 2008 Brian Lawler	ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
Search Engine Watch August 6, 2008 Kevin Ryan	Woohoo for Yahoo Even after the vote re-count, a majority of shareholders voted Yahoo's board in, and Carl Icahn settled for the right to propose two board seats and a spot for himself. At the end of the day, what's more important than rebuilding the Web's biggest brand?
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool September 22, 2008 Brian Lawler	Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems.
The Motley Fool October 12, 2005 W.D. Crotty	Icahn's Case for Time Warner Carl Icahn issues an open letter to shareholders pushing for change on the company's board. Investors should realize, though, that just because Icahn is around, that doesn't mean their shares will automatically go up.
The Motley Fool October 2, 2008 Brian Orelli	Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal?
The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool February 8, 2006 Rick Aristotle Munarriz	Time Warner's Splitting Headache Carl Icahn's investment banker suggests Time Warner break up into four pieces. But the company is doing its part to make investors know that it's not asleep at the wheel. With every quarterly improvement, Icahn's voice is likely to grow that much quieter.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool February 17, 2006 Rick Aristotle Munarriz	A Time for Peace Carl Icahn appears to have come to a truce with Time Warner over his breakup plans. However, a significant show of shareholders siding with Icahn's nominees may also force Time Warner to take a harder look at why it can't seem to get its stock out of the high teens.
The Motley Fool December 10, 2007 Brian Lawler	ImClone in a Giving Mood ImClone Systems and partner Sanofi-Aventis each decide to shell out $60 million to settle a lawsuit over the patents on cancer therapy Erbitux.
The Motley Fool August 12, 2005 Tom Taulli	Big Game Hunter As usual, Carl Icahn has a good sense of shifts in Corporate America. By taking a position on Time Warner, he's certainly going to be heard. And divvying up some of the assets may produce higher returns for shareholders as well.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool November 30, 2005 Rick Aristotle Munarriz	I Think Icahn, Time Warner Despite the market's interest in Time Warner's online operations, billionaire investor Carl Icahn still believes that more can be done to improve shareholder value.
The Motley Fool March 23, 2005 Stephen D. Simpson	Kerr-McGee Gets the Message Will this deepwater driller, a historical underachiever, succeed in acting in shareholders' best interests?
InternetNews January 30, 2007 Ed Sutherland	Icahn Has Motorola in His Sites News Wall Street trader Carl Icahn wants a spot on Motorola's board sent tongues wagging and stock prices up.
The Motley Fool April 21, 2005 Timothy M. Otte	Brawling at Blockbuster What's with this war of words between corporate raider Carl Icahn and Blockbuster management?
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool May 15, 2008 Rich Smith	The Icahn Man Cometh Morning business briefs: Carl Icahn makes a play for Yahoo!'s board... Merck wins a Vioxx lawsuit in Texas... Interpreting recent inflation data...
The Motley Fool May 12, 2005 Rick Aristotle Munarriz	Icahn's Blockbuster Move Billionaire investor Carl Icahn wins a spot on the Blockbuster board, but that's only the beginning. Blockbuster has really been trying the patience of its shareholders lately.
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
The Motley Fool June 19, 2008 Brian Orelli	Live From Bio: Activist Investors Activist investors throw a fit and try to get management changes when they're not happy, like Carl Icahn has done with ImClone Systems and tried to do with Biogen Idec. As they become more common, how are companies dealing with them?
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
The Motley Fool December 1, 2008 Rich Duprey	Corporate Boards Are Broken Extreme measures are needed to get boards to do their jobs.
The Motley Fool July 22, 2011 Evan Niu	Clorox to Icahn: "It's Not You, It's Me" Clorox announces that its board has unanimously rejected Icahn's unsolicited bid to acquire the company.
The Motley Fool September 1, 2005 Steven Mallas	Time for Time Warner? Time Warner has seen some interesting times lately. Should you buy the stock?
The Motley Fool June 15, 2010 Ryan McBride	Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.
The Motley Fool June 22, 2011	Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011.
The Motley Fool November 8, 2005 Rich Duprey	Fairmont's Fair Game for Icahn Financier takes a stake in the luxury resort chain Fairmont Hotels & Resorts to maximize undervalued assets. These plans should really come as no surprise to Fairmont investors.
The Motley Fool February 6, 2009 Brian Orelli	Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board.
The Motley Fool February 16, 2007 Brian Lawler	The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc.
The Motley Fool July 8, 2008 Rick Aristotle Munarriz	Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!.
The Motley Fool May 5, 2005 Rick Aristotle Munarriz	Make It a Blockbuster Fight Blockbuster and Carl Icahn are just days away from a battle at the company's shareholder meeting. Given Blockbuster's deteriorating financials and the sector's quickly changing landscape, it's hard to value the company based on its future prospects.
The Motley Fool April 27, 2007 Brian Lawler	Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note.
InternetNews March 24, 2008 Judy Mottl	Icahn Challenges Motorola on Handheld Strategy Motorola stockholder and longtime critic Carl Icahn is seeking answers about the company's floundering performance, filing a lawsuit today seeking documents related to Moto's beleaguered mobile device division.